Given that in several mouse models of autoimmune disease, including experimental autoimmune encephalomyelitis, diabetes, or psoriasis, endogenous non-toxic AHR ligands have already been successfully tested as potent immunosuppressive agents [12, 16, 17], it is conceivable that such AHR ligands might also be of therapeutic value in autoimmune diseases targeting the liver. Here, AHR is linked to diabetes mellitus.